Mirvetuximab Soravtansine联合吉西他滨治疗FRα阳性复发性卵巢癌、原发性腹膜癌、输卵管癌或子宫内膜癌及三阴性乳腺癌的I期研究
这项I期研究评估Mirvetuximab Soravtansine联合吉西他滨在FRα阳性复发性铂耐药上皮性卵巢癌、子宫内膜癌或三阴性乳腺癌患者中的最大耐受剂量和推荐II期剂量。20例患者入组,17例可评估剂量限制性毒性,最大耐受剂量/推荐II期剂量为MIRV 6 mg/kg AIBW第1天联合吉西他滨800 mg/m2静脉注射第1天和第8天,每21天一次(剂量水平3),该剂量下5/7例患者最佳反应为部分缓解。结论认为该方案在推荐II期剂量下对铂耐药上皮性卵巢癌显示有前景的活性,但血液学毒性频繁。
要点
- 最大耐受剂量/推荐II期剂量为MIRV 6 mg/kg AIBW第1天联合吉西他滨800 mg/m2静脉注射第1天和第8天,每21天一次(剂量水平3)。
- 推荐II期剂量下5/7例患者最佳反应为部分缓解,其中2例确认的卵巢癌缓解者至进展时间和缓解持续时间分别为7.9/5.4个月和8.0/5.7个月。
- 推荐II期剂量下最常见治疗相关不良事件为贫血和中性粒细胞减少(各3/7,43%),腹泻、低磷血症、血小板减少和白细胞减少(各2/7,29%)。
核心结论
- MIRV联合吉西他滨在推荐II期剂量下对铂耐药上皮性卵巢癌显示有前景的活性,但血液学毒性频繁。
研究设计与样本
- I期研究,入组FRα阳性铂耐药上皮性卵巢癌、子宫内膜癌或三阴性乳腺癌患者,既往化疗方案≤4线(子宫内膜癌为2线)。
- 共20例患者入组,其中17例可评估剂量限制性毒性。
- FRα表达要求因 eligible 肿瘤类型而异,并在研究过程中发生变化。
主要发现
- 半数患者接受过≥3线既往化疗。
- 大多数上皮性卵巢癌和子宫内膜癌患者(78%)为中等(50-74%)或高(75-100%)FRα表达者,三阴性乳腺癌患者为低(25-49%)FRα表达者。
- 最大耐受剂量/推荐II期剂量为MIRV 6 mg/kg AIBW第1天联合吉西他滨800 mg/m2静脉注射第1天和第8天,每21天一次(剂量水平3),该剂量下5/7例患者最佳反应为部分缓解。
- 2例确认的卵巢癌缓解者至进展时间和缓解持续时间分别为7.9/5.4个月和8.0/5.7个月。
- 推荐II期剂量下最常见治疗相关不良事件为贫血和中性粒细胞减少(各3/7,43%),腹泻、低磷血症、血小板减少和白细胞减少(各2/7,29%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Platinum-resistant epithelial ovarian cancer (EOC), recurrent endometrial cancer (EC), and triple negative breast cancer (TNBC) are difficult to treat after failing standard therapies. This phase I study evaluated mirvetuximab soravtansine (MIRV) and gemcitabine in patients with recurrent FRα-positive EOC, EC, or TNBC to determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) (primary endpoint). METHODS: FRα-positive patients with platinum-resistant EOC, EC, or TNBC with ≤4 prior chemotherapy regimens (2 for EC) were enrolled. FRα expression requirement varied among eligible tumors and changed during the study. RESULTS: Twenty patients were enrolled; 17 were evaluable for DLT. Half the patients received ≥3 prior chemotherapy lines. Most EOC and EC patients (78%) were medium (50-74%) or high(75-100%) FRα expressors. TNBC patients were low (25-49%) FRα expressors. The MTD/RP2D was MIRV 6 mg/kg AIBW D1 and gemcitabine 800 mg/m2 IV, D1 and D8, every 21 days (Dose Level [DL] 3), where 5/7 patients demonstrated a partial response (PR) as their best response, including 2 confirmed ovarian responses whose time-to-progression and duration of response were 7.9/5.4 and 8.0/5.7 months respectively. Most common treatment-related adverse events at MTD were anemia and neutropenia (3/7 each, 43%), diarrhea, hypophosphatemia, thrombocytopenia, and leukopenia (2/7 each, 29%). DLTs were thrombocytopenia (DL1), oral mucositis (DL4) and diarrhea (DL4). Nine of 20 patients (45%; 95% CI: 21.1-68.9%) achieved PR as their best response, with 3/20 patients or 15% (95%CI, 0-32.1%) confirmed PR. CONCLUSION: MIRV and gemcitabine demonstrate promising activity in platinum resistant EOC at RP2D, but frequent hematologic toxicities.
引用
- Cristea MC, Stewart D, Synold T, et al. A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer. Gynecol Oncol. 2024. PMID: 38262235. doi:10.1016/j.ygyno.2023.12.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。